33.87 USD
-0.08 (-0.24%)
34.62 USD
+0.75 (+2.21%)
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 528 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes GMAB very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year GMAB was profitable.
- GMAB had a positive operating cash flow in the past year.
- GMAB had positive earnings in each of the past 5 years.
- GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 21.10%, GMAB belongs to the top of the industry, outperforming 97.35% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 25.76%, GMAB belongs to the top of the industry, outperforming 97.16% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.78% of the companies in the same industry.
- GMAB had an Average Return On Invested Capital over the past 3 years of 15.20%. This is below the industry average of 18.28%.
- The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- Looking at the Profit Margin, with a value of 41.35%, GMAB belongs to the top of the industry, outperforming 97.16% of the companies in the same industry.
- In the last couple of years the Profit Margin of GMAB has declined.
- GMAB has a Operating Margin of 36.85%. This is amongst the best in the industry. GMAB outperforms 97.73% of its industry peers.
- In the last couple of years the Operating Margin of GMAB has declined.
- The Gross Margin of GMAB (94.27%) is better than 94.89% of its industry peers.
- In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
- Compared to 1 year ago, GMAB has less shares outstanding
- The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
- The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
- GMAB has an Altman-Z score of 12.43. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
- GMAB has a better Altman-Z score (12.43) than 84.66% of its industry peers.
- The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.12, GMAB belongs to the top of the industry, outperforming 95.83% of the companies in the same industry.
- A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.02, GMAB is in line with its industry, outperforming 43.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.43 |
ROIC/WACC2.45
WACC6.99%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
- GMAB has a Current ratio of 6.03. This is in the better half of the industry: GMAB outperforms 63.07% of its industry peers.
- GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of GMAB (6.01) is better than 64.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.90%, which is quite impressive.
- The Earnings Per Share has been growing by 28.38% on average over the past years. This is a very strong growth
- GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.66%.
- The Revenue has been growing by 31.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
- The Revenue is expected to grow by 13.38% on average over the next years. This is quite good.
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 14.35, GMAB is valued correctly.
- Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 96.40% of the companies are valued more expensively.
- GMAB is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 19.21 indicates a rather expensive valuation of GMAB.
- GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 94.32% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, GMAB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.35 | ||
| Fwd PE | 19.21 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 96.40% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 96.02% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.33 | ||
| EV/EBITDA | 11.5 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)5.09
PEG (5Y)0.51
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
5. Dividend
5.1 Amount
- GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
33.87
-0.08 (-0.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.86B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target38.24 (12.9%)
Short Float %1.95%
Short Ratio6.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.82%
EPS NQ rev (3m)8.48%
EPS NY rev (1m)0.04%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.35 | ||
| Fwd PE | 19.21 | ||
| P/S | 5.82 | ||
| P/FCF | 17.33 | ||
| P/OCF | 16.37 | ||
| P/B | 3.63 | ||
| P/tB | 5.72 | ||
| EV/EBITDA | 11.5 |
EPS(TTM)2.36
EY6.97%
EPS(NY)1.76
Fwd EY5.21%
FCF(TTM)1.95
FCFY5.77%
OCF(TTM)2.07
OCFY6.11%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)5.09
PEG (5Y)0.51
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 12.43 |
F-Score7
WACC6.99%
ROIC/WACC2.45
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.35 and the Price/Book (PB) ratio is 3.63.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.